DSIP
L-tryptophyl-L-alanyl-glycyl-glycyl-L-aspartyl-L-alanyl-L-seryl-glycyl-L-glutamic acid
DSIP is a naturally occurring nonapeptide identified in 1977 from rabbit cerebral venous blood, comprising nine amino acids in the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. This linear, hydrophilic peptide maintains its endogenous structure without synthetic modifications, making it ideal for sleep regulation research, stress response modulation, and central nervous system function studies in controlled experimental settings.
Complete Research Database
Adverse Event Frequencies (Clinical Trials)
Clinical Safety Notes
- •GI side effects typically occur during dose escalation
- •Most adverse events are mild to moderate in severity
- •Discontinuation rate due to side effects: ~5.3%
- •No increased risk of pancreatitis in clinical trials
- •Regular monitoring recommended for thyroid function
Medical Disclaimer
DSIP is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings.